Anebulo Pharmaceuticals (ANEB) Competitors $2.46 +0.01 (+0.41%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. FULC, AURA, YMAB, INBX, ADCT, CGEM, BNTC, DMAC, MNPR, and UPXIShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Fulcrum Therapeutics (FULC), Aura Biosciences (AURA), Y-mAbs Therapeutics (YMAB), Inhibrx Biosciences (INBX), ADC Therapeutics (ADCT), Cullinan Therapeutics (CGEM), Benitec Biopharma (BNTC), DiaMedica Therapeutics (DMAC), Monopar Therapeutics (MNPR), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors Fulcrum Therapeutics Aura Biosciences Y-mAbs Therapeutics Inhibrx Biosciences ADC Therapeutics Cullinan Therapeutics Benitec Biopharma DiaMedica Therapeutics Monopar Therapeutics Upexi Fulcrum Therapeutics (NASDAQ:FULC) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Do institutionals & insiders believe in FULC or ANEB? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer FULC or ANEB? Fulcrum Therapeutics presently has a consensus target price of $9.60, indicating a potential upside of 14.29%. Anebulo Pharmaceuticals has a consensus target price of $5.50, indicating a potential upside of 123.58%. Given Anebulo Pharmaceuticals' higher possible upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, FULC or ANEB? Fulcrum Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.89, meaning that its stock price is 189% less volatile than the S&P 500. Does the media prefer FULC or ANEB? In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 4 mentions for Fulcrum Therapeutics and 3 mentions for Anebulo Pharmaceuticals. Fulcrum Therapeutics' average media sentiment score of 1.42 beat Anebulo Pharmaceuticals' score of 0.95 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anebulo Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, FULC or ANEB? Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum TherapeuticsN/AN/A-$9.73M-$1.22-6.89Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-9.46 Is FULC or ANEB more profitable? Fulcrum Therapeutics' return on equity of -31.05% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -31.05% -28.96% Anebulo Pharmaceuticals N/A -90.11%-84.53% SummaryFulcrum Therapeutics beats Anebulo Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.02M$3.07B$5.65B$10.26BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-9.4620.6875.7026.05Price / SalesN/A397.57514.05168.79Price / CashN/A45.9137.5661.52Price / Book16.409.6212.876.29Net Income-$8.20M-$52.73M$3.29B$270.94M7 Day Performance-0.40%0.59%-0.33%-0.30%1 Month Performance-8.89%6.27%3.77%6.20%1 Year Performance32.97%18.55%68.18%28.32% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.3427 of 5 stars$2.46+0.4%$5.50+123.6%+17.2%$101.02MN/A-9.464FULCFulcrum Therapeutics1.9446 of 5 stars$7.31+3.4%$9.60+31.3%+157.0%$395.41MN/A-5.99100Positive NewsAURAAura Biosciences2.0503 of 5 stars$6.36+6.6%$22.00+245.8%-32.2%$395.21MN/A-3.2550Positive NewsYMABY-mAbs Therapeutics1.6269 of 5 stars$8.60+0.1%$9.62+11.9%N/A$390.77M$85.39M-17.20150INBXInhibrx Biosciences1.1404 of 5 stars$26.56-2.3%N/A+91.6%$384.72M$1.40M-2.51166Positive NewsADCTADC Therapeutics2.1114 of 5 stars$3.34+4.2%$7.75+132.4%+16.6%$374.06M$77.25M-2.12310CGEMCullinan Therapeutics2.3358 of 5 stars$6.33-0.4%$27.67+337.4%-65.8%$373.64MN/A-1.9630Positive NewsBNTCBenitec Biopharma1.7939 of 5 stars$13.86+1.1%$24.80+79.0%+57.6%$363.69M$80K-9.1820Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionDMACDiaMedica Therapeutics2.1748 of 5 stars$6.99-0.4%$12.33+76.6%+70.0%$361.82MN/A-10.1420Positive NewsMNPRMonopar Therapeutics2.4698 of 5 stars$58.05+6.5%$71.75+23.6%+1,556.2%$358.17MN/A-17.4310News CoverageAnalyst ForecastGap UpUPXIUpexi3.4677 of 5 stars$6.03-4.7%$15.50+156.9%+45.4%$355.34M$26M0.00130News CoveragePositive NewsUpcoming EarningsGap Down Related Companies and Tools Related Companies Fulcrum Therapeutics Alternatives Aura Biosciences Alternatives Y-mAbs Therapeutics Alternatives Inhibrx Biosciences Alternatives ADC Therapeutics Alternatives Cullinan Therapeutics Alternatives Benitec Biopharma Alternatives DiaMedica Therapeutics Alternatives Monopar Therapeutics Alternatives Upexi Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
